HRP970246B1 - Substituted oxobutric acids as matrix metalloprotease inhibitors - Google Patents

Substituted oxobutric acids as matrix metalloprotease inhibitors

Info

Publication number
HRP970246B1
HRP970246B1 HR970246A HRP970246A HRP970246B1 HR P970246 B1 HRP970246 B1 HR P970246B1 HR 970246 A HR970246 A HR 970246A HR P970246 A HRP970246 A HR P970246A HR P970246 B1 HRP970246 B1 HR P970246B1
Authority
HR
Croatia
Prior art keywords
oxobutric
acids
substituted
matrix metalloprotease
metalloprotease inhibitors
Prior art date
Application number
HR970246A
Other languages
English (en)
Inventor
Brian R Dixon
Jinshan Chen
Michael Van Zandt
David R Brittelli
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HRP970246A2 publication Critical patent/HRP970246A2/xx
Publication of HRP970246B1 publication Critical patent/HRP970246B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HR970246A 1996-05-15 1997-05-09 Substituted oxobutric acids as matrix metalloprotease inhibitors HRP970246B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (2)

Publication Number Publication Date
HRP970246A2 HRP970246A2 (en) 1998-04-30
HRP970246B1 true HRP970246B1 (en) 2002-04-30

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970246A HRP970246B1 (en) 1996-05-15 1997-05-09 Substituted oxobutric acids as matrix metalloprotease inhibitors

Country Status (18)

Country Link
EP (1) EP0912487A1 (id)
JP (1) JP3417951B2 (id)
CN (1) CN1163466C (id)
AR (1) AR007096A1 (id)
AU (1) AU727648B2 (id)
CA (1) CA2253869C (id)
CO (1) CO4990925A1 (id)
HR (1) HRP970246B1 (id)
ID (1) ID20291A (id)
MY (1) MY132470A (id)
PA (1) PA8429401A1 (id)
PE (1) PE65998A1 (id)
SV (1) SV1997000034A (id)
TN (1) TNSN97085A1 (id)
TW (1) TW467892B (id)
WO (1) WO1997043238A1 (id)
YU (1) YU18797A (id)
ZA (1) ZA974032B (id)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2696041A1 (en) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
EP3126358A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
WO2015150362A2 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT74511A (en) * 1994-01-22 1997-01-28 British Biotech Pharm Metalloproteinase inhibitors, pharmaceutical compns. contg. them and process to prepare the said compds.
PL327494A1 (en) 1995-12-22 1998-12-21 Warner Lambert Co Aromatic keto-carboxylic acids and their derivatives as inhibitors of matrix metalloproteinases
CO5011071A1 (es) 1996-05-15 2001-02-28 Bayer Corp Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen

Also Published As

Publication number Publication date
PA8429401A1 (es) 2000-05-24
WO1997043238A1 (en) 1997-11-20
ZA974032B (en) 1998-02-19
CA2253869A1 (en) 1997-11-20
AR007096A1 (es) 1999-10-13
CN1225622A (zh) 1999-08-11
AU3121997A (en) 1997-12-05
SV1997000034A (es) 1999-07-05
JPH11509870A (ja) 1999-08-31
AU727648B2 (en) 2000-12-21
ID20291A (id) 1998-11-19
TW467892B (en) 2001-12-11
HRP970246A2 (en) 1998-04-30
CN1163466C (zh) 2004-08-25
CO4990925A1 (es) 2000-12-26
EP0912487A1 (en) 1999-05-06
TNSN97085A1 (fr) 2005-03-15
YU18797A (en) 1999-11-22
JP3417951B2 (ja) 2003-06-16
MY132470A (en) 2007-10-31
CA2253869C (en) 2003-04-22
PE65998A1 (es) 1998-10-20

Similar Documents

Publication Publication Date Title
IL128668A0 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
ZA959948B (en) Matrix metalloprotease inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
IL128663A0 (en) 1,4-heterocyclic metalloprotease inhibitors
IL128661A0 (en) 1,3-diheterocyclic metalloprotease inhibitors
AU3102397A (en) Metalloprotease inhibitors
HU9801045D0 (en) Substituted diamino-carboxylic acids
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
IL128665A0 (en) Bidenatate metalloprotease inhibitors
ZA96850B (en) Matrix metalloprotease inhibitors.
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
HUP9904664A3 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
GB9613547D0 (en) Matrix metalloproteinase inhibitors
IL136889A0 (en) Matrix metalloprotease inhibitors
IL115995A0 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
HRP970247A2 (en) Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
HRP970245B1 (en) Biaryl acetilenes as matrix metalloprotease inhibitors
HRP970246B1 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
HK1020965A (en) Phosphinic acid amides as matrix metalloprotease inhibitors
ZA9610604B (en) Matrix metalloprotease inhibitors
GB9702085D0 (en) Matrix metalloproteinase inhibitors
SI0901466T1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
GB9415619D0 (en) Metalloprotease inhibitors
SI0790974T1 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
GB9605047D0 (en) Naphthyl glyozamides as sPLA2 inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040428

Year of fee payment: 8

PBON Lapse due to non-payment of renewal fee

Effective date: 20050510